Gordon Carl L's Form 4 filing
Kinnate Biopharma Inc. (KNTE) · filed May 2, 2023
- Accession no.
- 0000947871-23-000516
- Filed
- May 2, 2023
- Trade date
- Apr 28-May 2, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 9 non-derivative transactions. Open-market purchases total $3.67M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gordon Carl LCIK 0001282930 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 28, 2023 | Common Stock | PPurchaseAcquired | +60,998 | $2.55 | +$155,544.9 | 610,998 | Indirect | |
| Apr 28, 2023 | Common Stock | PPurchaseAcquired | +228,754 | $2.55 | +$583,322.7 | 3,737,784 | Indirect | |
| Apr 28, 2023 | Common Stock | PPurchaseAcquired | +60,997 | $2.55 | +$155,542.35 | 610,997 | Indirect | |
| May 1, 2023 | Common Stock | PPurchaseAcquired | +124,544 | $2.62F4 | +$326,305.28 | 735,542 | Indirect | |
| May 1, 2023 | Common Stock | PPurchaseAcquired | +467,068 | $2.62F4 | +$1,223,718.16 | 4,204,852 | Indirect | |
| May 1, 2023 | Common Stock | PPurchaseAcquired | +124,545 | $2.62F4 | +$326,307.9 | 735,542 | Indirect | |
| May 2, 2023 | Common Stock | PPurchaseAcquired | +58,826 | $2.67F5 | +$157,065.42 | 794,368 | Indirect | |
| May 2, 2023 | Common Stock | PPurchaseAcquired | +220,610 | $2.67F5 | +$589,028.7 | 4,425,462 | Indirect | |
| May 2, 2023 | Common Stock | PPurchaseAcquired | +58,826 | $2.67F5 | +$157,065.42 | 794,368 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F4
Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.59 to a high of $2.64 per share. The Reporting Persons undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price.
Referenced by the price of 3 transactions in Table I.
- F5
Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.57 to a high of $2.82 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price.
Referenced by the price of 3 transactions in Table I.